Relevance of Minor Neuropsychological Deficits in Patients With Subjective Cognitive Decline

Stark, Melina; Wolfsgruber, Steffen; Kleineidam, Luca; Frommann, Ingo; Altenstein, Slawek; Bartels, Claudia; Brosseron, Frederic; Buerger, Katharina; Burow, Lena; Butryn, Michaela; Ewers, Michael; Fliessbach, Klaus; Gabelin, Tatjana; Glanz, Wenzel; Goerss, Doreen; Gref, Daria; Hansen, Niels; Heneka, Michael T.; Hinderer, Petra; Incesoy, Enise I.; Janowitz, Daniel; Kilimann, Ingo; Kimmich, Okka; Laske, Christoph; Munk, Matthias H.; Perneczky, Robert; Peters, Oliver; Preis, Lukas; Priller, Josef; Rauchmann, Boris-Stephan; Rostamzadeh, Ayda; Roy-Kluth, Nina; Sanzenbacher, Carolin; Schneider, Anja; Schott, Bjoern H.; Spottke, Annika; Spruth, Eike Jakob; Teipel, Stefan; Vogt, Ina R.; Wiltfang, Jens; Duzel, Emrah; Jessen, Frank und Wagner, Michael (2023): Relevance of Minor Neuropsychological Deficits in Patients With Subjective Cognitive Decline. In: Neurology, Bd. 101, Nr. 21, E2185-E2196

Abstract

Background and ObjectivesTo determine the relevance of minor neuropsychological deficits (MNPD) in patients with subjective cognitive decline (SCD) with regard to CSF levels of Alzheimer disease (AD) biomarkers, cognitive decline, and clinical progression to mild cognitive impairment (MCI).MethodsThis study included patients with clinical SCD and SCD-free, healthy control (HC) participants with available baseline CSF and/or longitudinal cognitive data from the observational DZNE Longitudinal Cognitive Impairment and Dementia study. We defined MNPD as a performance of at least 0.5SD below the mean on a demographically adjusted total score derived from the Consortium to Establish a Registry for Alzheimer's Disease neuropsychological assessment battery. We compared SCD patients with MNPD and those without MNPD with regard to CSF amyloid-beta (A beta)42/A beta 40, phosphorylated tau (p-tau181), total tau and A beta 42/p-tau181 levels, longitudinal cognitive composite trajectories, and risk of clinical progression to incident MCI (follow-up M +/- SD: 40.6 +/- 23.7 months). In addition, we explored group differences between SCD and HC in those without MNPD.ResultsIn our sample (N = 672, mean age: 70.7 +/- 5.9 years, 50% female), SCD patients with MNPD (n = 55, 12.5% of SCD group) showed significantly more abnormal CSF biomarker levels, increased cognitive decline, and a higher risk of progression to incident MCI (HR: 4.07, 95% CI 2.46-6.74) compared with SCD patients without MNPD (n = 384). MNPD had a positive predictive value of 57.0% (95% CI 38.5-75.4) and a negative predictive value of 86.0% (95% CI 81.9-90.1) for the progression of SCD to MCI within 3 years. SCD patients without MNPD showed increased cognitive decline and a higher risk of incident MCI compared with HC participants without MNPD (n = 215;HR: 4.09, 95% CI 2.07-8.09), while AD biomarker levels did not differ significantly between these groups.DiscussionOur results suggest that MNPD are a risk factor for AD-related clinical progression in cognitively normal patients seeking medical counseling because of SCD. As such, the assessment of MNPD could be useful for individual clinical prediction and for AD risk stratification in clinical trials. However, SCD remains a risk factor for future cognitive decline even in the absence of MNPD.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin > Munich Cluster for Systems Neurology (SyNergy)
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• Sprache: Englisch
• DFG: Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198